DK3851107T3 - Heteroaryl-ketonkondenseret azadecalin som glucocorticoidreceptormodulatorer - Google Patents

Heteroaryl-ketonkondenseret azadecalin som glucocorticoidreceptormodulatorer Download PDF

Info

Publication number
DK3851107T3
DK3851107T3 DK21154665.0T DK21154665T DK3851107T3 DK 3851107 T3 DK3851107 T3 DK 3851107T3 DK 21154665 T DK21154665 T DK 21154665T DK 3851107 T3 DK3851107 T3 DK 3851107T3
Authority
DK
Denmark
Prior art keywords
receptor modulators
glucocorticoid receptor
fused azadecalin
heteroaryl ketone
heteroaryl
Prior art date
Application number
DK21154665.0T
Other languages
Danish (da)
English (en)
Inventor
Nicholas Ray
Iain Walters
Hazel Hunt
Tony Johnson
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Application granted granted Critical
Publication of DK3851107T3 publication Critical patent/DK3851107T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53831,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Electroluminescent Light Sources (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK21154665.0T 2012-05-25 2013-05-24 Heteroaryl-ketonkondenseret azadecalin som glucocorticoidreceptormodulatorer DK3851107T3 (da)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261651669P 2012-05-25 2012-05-25
US201261691083P 2012-08-20 2012-08-20
US201261715907P 2012-10-19 2012-10-19
US201361759520P 2013-02-01 2013-02-01
US201361781629P 2013-03-14 2013-03-14
EP19188885.8A EP3590517B1 (en) 2012-05-25 2013-05-24 Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators

Publications (1)

Publication Number Publication Date
DK3851107T3 true DK3851107T3 (da) 2022-11-21

Family

ID=49624542

Family Applications (5)

Application Number Title Priority Date Filing Date
DK21154665.0T DK3851107T3 (da) 2012-05-25 2013-05-24 Heteroaryl-ketonkondenseret azadecalin som glucocorticoidreceptormodulatorer
DK13793417.0T DK2854814T3 (en) 2012-05-25 2013-05-24 Heteroberl ketone condensed azadecaline as modulators of glucocorticoid receptors
DK19188885.8T DK3590517T3 (da) 2012-05-25 2013-05-24 Heteroaryl-ketonkondenserede azadecalin som modulatorer af glucocorticoidreceptorer
DK22193438.3T DK4119561T3 (da) 2012-05-25 2013-05-24 Heteroaryl-ketonkondenserede azadecalin-glucocorticoidreceptormodulatorer
DK18154256T DK3338781T3 (da) 2012-05-25 2013-05-24 Heteroaryl-keton-kondenseret azadecalin som modulatorer af glucocorticoidreceptorer

Family Applications After (4)

Application Number Title Priority Date Filing Date
DK13793417.0T DK2854814T3 (en) 2012-05-25 2013-05-24 Heteroberl ketone condensed azadecaline as modulators of glucocorticoid receptors
DK19188885.8T DK3590517T3 (da) 2012-05-25 2013-05-24 Heteroaryl-ketonkondenserede azadecalin som modulatorer af glucocorticoidreceptorer
DK22193438.3T DK4119561T3 (da) 2012-05-25 2013-05-24 Heteroaryl-ketonkondenserede azadecalin-glucocorticoidreceptormodulatorer
DK18154256T DK3338781T3 (da) 2012-05-25 2013-05-24 Heteroaryl-keton-kondenseret azadecalin som modulatorer af glucocorticoidreceptorer

Country Status (24)

Country Link
EP (6) EP2854814B1 (enExample)
JP (1) JP6172871B2 (enExample)
KR (1) KR102062640B1 (enExample)
CN (1) CN104619328B (enExample)
AU (1) AU2013266110C1 (enExample)
BR (1) BR112014028857B1 (enExample)
CA (1) CA2872260C (enExample)
CL (1) CL2014003173A1 (enExample)
DK (5) DK3851107T3 (enExample)
ES (5) ES2930298T3 (enExample)
FI (1) FI4119561T3 (enExample)
HK (1) HK1250014B (enExample)
IL (1) IL235868A (enExample)
MX (1) MX365423B (enExample)
MY (1) MY172739A (enExample)
NZ (1) NZ701469A (enExample)
PE (1) PE20150352A1 (enExample)
PH (1) PH12014502584A1 (enExample)
PL (5) PL2854814T3 (enExample)
PT (5) PT4119561T (enExample)
RU (1) RU2639867C2 (enExample)
SG (1) SG11201407682TA (enExample)
WO (1) WO2013177559A2 (enExample)
ZA (1) ZA201408182B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12226412B2 (en) 2012-05-25 2025-02-18 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
MX368167B (es) 2013-11-25 2019-09-23 Corcept Therapeutics Inc Moduladores de receptores de glucocorticoides de azadecalina octahidro fusionada.
CN107530435A (zh) * 2015-03-02 2018-01-02 科赛普特治疗学股份有限公司 使用糖皮质激素受体拮抗剂和生长抑素治疗acth分泌型肿瘤
CN107530339B (zh) 2015-03-30 2021-03-16 科赛普特治疗学股份有限公司 糖皮质激素受体拮抗剂联合糖皮质激素用于治疗肾上腺功能不全
PH12017502099B1 (en) 2015-05-18 2023-08-30 Corcept Therapeutics Inc Methods for diagnosing and assessing treatment for cushing's syndrome
MX383318B (es) 2015-08-13 2025-03-13 Corcept Therapeutics Inc Metodo para diagnosticar de manera diferencial el sindrome de cushing dependiente de la corticotropina.
JP6847120B2 (ja) * 2016-03-01 2021-03-24 コーセプト セラピューティクス, インコーポレイテッド チェックポイントインヒビターを強化するためのグルココルチコイドレセプターモジュレーターの使用
US9943505B2 (en) 2016-09-09 2018-04-17 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat pancreatic cancer
US10413540B2 (en) 2017-03-31 2019-09-17 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat cervical cancer
MX393313B (es) 2017-06-20 2025-03-24 Corcept Therapeutics Inc Metodos de tratamiento de tumores neuroepiteliales usando moduladores selectivos del receptor de glucocorticoide.
ES3038908T3 (en) * 2018-04-23 2025-10-15 Corcept Therapeutics Inc Methods of preparing regioselective n-alkyl triazoles
WO2020097513A1 (en) * 2018-11-09 2020-05-14 Corcept Therapeutics Incorporated Methods for shrinking pituitary tumors
WO2020132046A1 (en) 2018-12-19 2020-06-25 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
CN117281790A (zh) 2018-12-19 2023-12-26 科塞普特治疗公司 含有瑞拉可兰、杂芳基-酮稠合的氮杂十氢化萘化合物的药物制剂
AU2019405771B2 (en) * 2018-12-20 2025-02-20 Corcept Therapeutics Incorporated Methods for imaging and treatment of somatostatin-receptor positive tumors
EP3927345A4 (en) 2019-02-22 2022-12-21 Corcept Therapeutics Incorporated Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
US12440487B2 (en) 2019-10-16 2025-10-14 Corcept Therapeutics Incorporated Method of normalizing the neutrophil to lymphocyte ratio in cancer patients with a selective glucocorticoid receptor antagonist
WO2021119432A1 (en) 2019-12-11 2021-06-17 Corcept Therapeutics Incorporated Methods of treating antipsychotic-induced weight gain with miricorilant
CA3162636A1 (en) 2019-12-21 2021-06-24 Andreas G. MORAITIS Treatment of, and differential diagnosis between, acth-dependent cushing's syndrome and acth-independent cushing's syndrome
MX2022009781A (es) * 2020-02-10 2022-09-09 Corcept Therapeutics Inc Metodos para estimular una respuesta antitumoral utilizando un modulador selectivo del receptor de glucocorticoides.
WO2022134033A1 (en) * 2020-12-25 2022-06-30 Corcept Therapeutics Incorporated Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
CN116829556A (zh) * 2021-02-03 2023-09-29 江苏恒瑞医药股份有限公司 稠合的氮杂三环类衍生物、其制备方法及其在医药上的应用
KR20250073629A (ko) * 2022-10-06 2025-05-27 코어셉트 쎄라퓨틱스 인코포레이티드 글루코코르티코이드 수용체 조절제의 제형
EP4608402A1 (en) 2022-10-28 2025-09-03 Corcept Therapeutics Incorporated Treatments for amyotrophic lateral sclerosis using dazucorilant
KR20250144469A (ko) * 2023-02-17 2025-10-10 코어셉트 쎄라퓨틱스 인코포레이티드 헌팅턴병 및 이의 증상을 치료하기 위한 방법 및 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
GB8828669D0 (en) * 1988-12-08 1989-01-11 Lilly Industries Ltd Organic compounds
ES2313317T3 (es) 2004-03-09 2009-03-01 Corcept Therapeutics, Inc. Moduladores del receptor de glucocorticoides de azadecalina de anillo condensado.
US7640389B2 (en) * 2006-02-28 2009-12-29 Freescale Semiconductor, Inc. Non-volatile memory having a multiple block erase mode and method therefor
EP1932843A1 (en) * 2006-12-14 2008-06-18 sanofi-aventis Sulfonyl-phenyl-2H-(1,2,4) oxadiazole-5-one derivatives, processes for their preparation and their use as pharmaceuticals
WO2012027702A1 (en) * 2010-08-27 2012-03-01 Corcept Therapeutics, Inc. Pyridyl-amine fused azadecalin modulators

Also Published As

Publication number Publication date
ES2930298T3 (es) 2022-12-09
PT3590517T (pt) 2021-04-07
MY172739A (en) 2019-12-11
PL3338781T3 (pl) 2020-03-31
BR112014028857A2 (pt) 2017-08-15
CN104619328A (zh) 2015-05-13
AU2013266110C1 (en) 2018-07-12
DK3590517T3 (da) 2021-05-03
MX365423B (es) 2019-06-03
CA2872260A1 (en) 2013-11-28
RU2639867C2 (ru) 2017-12-25
WO2013177559A2 (en) 2013-11-28
IL235868A (en) 2017-12-31
PT4119561T (pt) 2024-09-30
PL3851107T3 (pl) 2023-03-06
BR112014028857B1 (pt) 2021-09-28
MX2014014239A (es) 2015-08-05
EP4119561B1 (en) 2024-09-11
PH12014502584B1 (en) 2015-01-21
SG11201407682TA (en) 2014-12-30
PT2854814T (pt) 2018-03-15
AU2013266110A1 (en) 2014-11-20
PL4119561T3 (pl) 2024-11-25
EP2854814A2 (en) 2015-04-08
EP2854814A4 (en) 2016-01-27
CN104619328B (zh) 2018-10-02
EP4434584A2 (en) 2024-09-25
ES2665338T3 (es) 2018-04-25
PL2854814T3 (pl) 2018-07-31
ZA201408182B (en) 2017-09-27
PL3590517T3 (pl) 2021-09-20
JP6172871B2 (ja) 2017-08-02
WO2013177559A3 (en) 2014-01-16
RU2014152625A (ru) 2016-07-20
DK2854814T3 (en) 2018-03-12
IL235868A0 (en) 2015-01-29
PT3338781T (pt) 2019-11-29
NZ701469A (en) 2017-06-30
KR20150021955A (ko) 2015-03-03
ES2873949T3 (es) 2021-11-04
DK4119561T3 (da) 2024-09-30
DK3338781T3 (da) 2019-12-09
FI4119561T3 (fi) 2024-11-01
EP3338781A1 (en) 2018-06-27
ES2753816T3 (es) 2020-04-14
EP3590517A1 (en) 2020-01-08
EP4434584A3 (en) 2024-11-20
KR102062640B1 (ko) 2020-01-06
CL2014003173A1 (es) 2015-02-27
HK1208818A1 (en) 2016-03-18
CA2872260C (en) 2020-12-22
EP3851107B1 (en) 2022-10-19
PE20150352A1 (es) 2015-03-16
ES2995026T3 (en) 2025-02-05
EP2854814B1 (en) 2018-01-31
EP3851107A1 (en) 2021-07-21
PH12014502584A1 (en) 2015-01-21
EP3590517B1 (en) 2021-03-17
EP4119561A1 (en) 2023-01-18
EP3338781B1 (en) 2019-09-11
AU2013266110B2 (en) 2017-04-20
JP2015517580A (ja) 2015-06-22
HK1250014B (en) 2020-06-12
PT3851107T (pt) 2022-10-28

Similar Documents

Publication Publication Date Title
DK3851107T3 (da) Heteroaryl-ketonkondenseret azadecalin som glucocorticoidreceptormodulatorer
IL245848B (en) Octahydro fused azadecalin glucocorticoid receptor modulators
ME03081B (me) Modulatora receptora androgena patentni zahtevi
DK3723369T3 (da) Indretning til kortlægning af intraprædikationsmodus
DK2938615T3 (da) Imidazopyridazin-derivater som GABAA-receptormodulatorer
DK3385252T3 (da) Cannabinoidreceptormodulatorer
SMT201700009B (it) Modulatori del recettore x del fegato
EP2911666A4 (en) MODULATORS OF A RESISTANT ANDROGEN RECEPTOR
SMT201600374B (it) Modulatori del recettore x del fegato
IL231440A0 (en) Selective androgen receptor modulators
HUE036238T2 (hu) Szelektív androgén receptor modulátorokként ható indolkarbonitril vegyületek
IL235723A0 (en) A simplified device using innovative semiconductor pn structures
IL239076A0 (en) Novel and selective androgen receptor modulators
DK2903652T3 (da) Hydroxylerede polyaminderivater som transfektionsreagenser
DK2903651T3 (da) Carboxylerede polyaminderivater som transfektionsreagenser
EP2863742A4 (en) MICRO CAPSULE
DK3345899T3 (da) Benzofuran-2-sulfonamidderivater som kemokinreceptormodulatorer